New Drug's dance with statins and coffee revealed in human trial
NCT ID NCT06821698
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This study looked at how a new drug called KP-001 affects the way the body processes rosuvastatin (a cholesterol drug) and caffeine. It also tested how another drug, fluvoxamine, affects KP-001 levels. The trial involved 38 healthy adults and was designed to gather safety and interaction data, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parexel International Early Phase Clinical Unit
Glendale, California, 91206, United States
Conditions
Explore the condition pages connected to this study.